Status | Study |
Recruiting |
Study Name: Laser Tissue Welding - Distal Pancreatectomy Sealing Study Condition: Pancreatic Tumor, Benign Pancreatic Neoplasms Pancreatic A Date: 2017-05-08 Interventions: Device: Distal Pancreatectomy Sealing Using LTW The device's intended use is to seal the pancreatic surf |
Recruiting |
Study Name: Prospective Longitudinal Biomarker Study in Pancreatic Neuroendocrine Tumours Condition: Neuroendocrine Tumors Date: 2017-04-06 Interventions: Procedure: Core Needle Biopsy |
Recruiting |
Study Name: Asymptomatic Small Pancreatic Endocrine Neoplasms. Condition: Non Functioning Pancreatic Endocrine Tumor Date: 2017-03-06 Interventions: Diagnostic Test: Radiological imaging studies |
Recruiting |
Study Name: Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET) Condition: Multiple Endocrine Neoplasia Pancreatic Neuroendocrine Tumors Date: 2017-02-13 Interventions: Other: Genome Sequencing Analy |
Not yet recruiting |
Study Name: Pasireotide in Hyperinsulinemic Hypoglycemia Condition: Congenital Hyperinsulinism Insulinoma Hyperinsulinism Date: 2017-02-09 Interventions: Drug: Pasireotide 0.6Mg Solution for Injection |
Recruiting |
Study Name: Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients Condition: Multiple Endocrine Neoplasia Date: 2017-02-07 |
Recruiting |
Study Name: Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors) Condition: Genetic Mutation MEN1 Date: 2017-02-02 Interventions: Other: Chart Review Database r |
Not yet recruiting |
Study Name: Everolimus TDM to Predict Long Term Toxicity Condition: Breast Cancer Renal Cell Carcinoma Pancreatic Neuroendocri Date: 2017-01-24 |
Not yet recruiting |
Study Name: Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs Condition: Neuroendocrine Tumors Neoplasms Cancer Date: 2016-10-21 Interventions: Drug: TAS-102 Anti-metabolite |
Recruiting |
Study Name: Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery Condition: Pancreatic Neuroendocrine Tumor G1 Pancreatic Neuroendocrine Tumor G2 Date: 2016-09-08 Interventions: Drug: Sapanisertib Given PO Other Names: |